Aesthetic Medical International Holdings Group Limited

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 15 treatment centers in China, Hong Kong, and Singapore. Aesthetic Medical International Holdings Group Limited was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.

Aesthetic Medical International Holdings Group Limited trades as AIH on NASDAQ. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $682.59M of revenue and -$37.43M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Aesthetic Medical International Holdings Group Limited can be compared against peers such as AlphaTON Capital Corp., Cano Health, Inc., Chembio Diagnostics, Inc., COSCIENS Biopharma Inc., Enzo Biochem, Inc., Kineta, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $15.93M, beta of -0.20, and return on equity of -76.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AIH currently shows total debt of $244.55M and beta of -0.20. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 20-F (2026-04-23 00:00:00), SC 13D/A (2026-04-03 00:00:00), 6-K (2025-08-19 00:00:00), 20-F (2025-04-25 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://ir.aihgroup.net

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.